Xtant Medical Holdings, Inc. (XTNT) Q1 2025 Earnings Call Transcript
Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brett Maas - Hayden IR Sean Browne - President and Chief Executive Officer Scott Neils - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Ryan Zimmerman - BTIG Operator Good afternoon, everyone, and welcome to the Xtant Medical's First Quarter 2025 Financial Results. At this time, all participants are in a listen-only mode, and the floor will be open for questions following the presentation.
Xtant Medical Holdings, Inc. (XTNT) Q4 2024 Earnings Call Transcript
Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q4 2024 Results Conference Call March 6, 2025 4:30 PM ET Company Participants Brett Maas - Hayden IR Sean Browne - President & Chief Executive Officer Scott Neils - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good day, everyone, and welcome to the Xtant Medical Fourth Quarter and Year-End 2024 Earnings. At this time, all participants have been placed on a listen-only mode.
Xtant Medical Holdings, Inc. (XTNT) Q3 2024 Earnings Conference Call Transcript
Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Brett Maas - IR Sean Browne - President and CEO Scott Neils - CFO Conference Call Participants Operator Welcome to the Xtant Medical Holdings, Inc. Third Quarter 2024 Conference Call. At this time all participants are in a listen only mode.
Xtant Medical Reports Third Quarter 2024 Financial Results
Third Quarter Revenue Growth of 12% Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 Million Representing Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year period Gross margin of 58.4% compared to 61.3% for the prior year quarter Net loss of $5.0 million compared to net income of $9.2 million in the prior year quarter which included a $11.0 million bargain purchase gain related to the acquisition of Surgalign Holdings Adjusted EBITDA of $(196,000) compared to $440,000 in the prior year quarter Recent Business Highlights Launched OsteoVive+, a moldable, viable bone matrix for use in a variety of grafting procedures Launched Cortera Posterior Fixation System, a comprehensive solution designed to streamline thoracolumbar fixation surgeries Signed a license agreement for Q-Codes and corresponding SimpliMax Dual Layer Amniotic Membrane, which provides for a minimum of $5.25 million in licensing and royalty fees Completed $5.0 million private placement on August 9, 2024 Sean Browne, President and CEO of Xtant Medical, stated, "During the third quarter, we expanded our market opportunities with the launch of two new products, OsteoVive+ (stem cells) and Cortera Posterior Fixation System.
Xtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select Conference
BELGRADE, MT / ACCESSWIRE / November 11, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced announced that Sean Browne, CEO and Scott Neils, CFO will be attending the following upcoming conference: Event: 15th Annual Craig-Hallum Alpha Select Conference Date: November 19, 2024Location: Sheraton NY Times Square Hotel, New York, NYFormat: 1x1 Meetings For more information, please visit: Click Here About Xtant Medical Holdings, Inc. Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures.
Xtant Medical to Issue Third Quarter 2024 Financial Results on November 12, 2024
BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.
Xtant Medical Holdings, Inc. (XTNT) Q2 2024 Earnings Call Transcript
Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Brett Maas - IR Sean Browne - President and CEO Scott Neils - CFO Conference Call Participants Ryan Zimmerman - BTIG Chase Knickerbocker - Craig-Hallum Capital Operator Welcome to the Xtant Medical Holdings, Inc. Second Quarter 2024 Conference Call. [Operator Instructions] I would now like to turn the call over to your host, Brett Maas, IR.
Xtant Medical Announces Closing of $5.0 Million Private Placement
BELGRADE, MT / ACCESSWIRE / August 9, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $5.0 million private placement with an existing institutional investor. The Company sold 7,812,500 shares of common stock at a purchase price of $0.64 per share.
Xtant Medical Announces $5.0 Million Private Placement
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with an existing institutional investor to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 7,812,500 shares of common stock at a purchase price of $0.64 per share, resulting in gross proceeds of $5.0 million.
Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.
Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $29.9 million, up 48%, compared to the prior year quarter Gross margin of 62.1%, up 50 basis points, compared to the prior year quarter Net loss of $3.9 million compared to $2.2 million in the year ago quarter Positive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarter Recent Business Highlights Recently launched two new amniotic membrane allografts products, SimpliGraftâ„¢ and SimpliMaxâ„¢; while Corteraâ„¢ reached record sales and users for the second quarter Signed 15 new distributors in the second quarter Awarded 20 IDN contracts in the second quarter Entered into a $5.0 million private placement on August 7, 2024 Sean Browne, President and CEO of Xtant Medical, stated, "Our second quarter financial results illustrate the positive momentum that is building as we head into the second half of 2024.
Xtant Medical to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
BELGRADE, MT / ACCESSWIRE / July 25, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will attend the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase being held August 13-15, 2024 at the InterContinental Boston, an IHG Hotel. Sean Browne, President and Chief Executive Officer will present on Wednesday, August 14th at 11:00 a.m.
